Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.52 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.52 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13458070 | 0.94 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL1752786 | 0.84 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL4651399 | 0.84 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL220069 | 0.84 | SMARCA2 (0.52) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL24689396 | 0.84 | SMARCA2 (0.52) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL23731087 | 0.84 | CYP1A2 (0.64) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL18725079 | 0.84 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL240423 | 0.84 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL21202930 | 0.84 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL423171 | 0.84 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2USP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285415-A | Cis-2-alkene-1, 4-diketone derivative and synthetic method thereof | 浙江师范大学 | 2023-12-26 | — | — | CN | disclosed |
| US-8330039-B2 | Solar cell modules with poly(vinyl butyral) encapsulant comprising unsaturated heterocyclic compound | E I DU PONT DE NEMOURS AND COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| CN-102292826-A | Solar cell modules with poly(vinyl butyral) encapsulant comprising unsaturated heterocyclic compound | — | 2011-12-21 | — | — | CN | disclosed |
| EP-2380208-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. du Pont de Nemours and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010085664-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20100180947-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
| EP-2168576-A2 | New utilities of tricyclic compounds | Shionogi & Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20080318958-A1 | New utilities of tricyclic compounds | ISHIZUKA NATSUKI | 2008-12-25 | — | — | US | disclosed |
| US-20080318958-A1 | New utilities of tricyclic compounds | ISHIZUKA NATSUKI | 2008-12-25 | — | — | US | disclosed |
| CN-1937995-A | Keratin dyeing compositions comprising bicyclic 5-6 heteroaromatic dyeing compounds containing a ring-connected nitrogen atom | PROCTER & GAMBLE (US) | 2007-03-28 | — | — | CN | disclosed |
| EP-0260910-B1 | 3,6-DIPHENYLPYRIDAZINES | Chisso Corporation (JP) | 1992-05-27 | — | — | EP | disclosed |
| US-4818430-A | LIQUID CRYSTALS | CHISSO CORPORATION (JP) | 1989-04-04 | — | — | US | disclosed |
| EP-0260910-A1 | 3,6-Diphenylpyridazines | Chisso Corporation (JP) | 1988-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318958-A1 | New utilities of tricyclic compounds | APOB, PON1, APOL1 | RAB9A 3868/4885NPC1 35/4885SMN1; SMN2 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.